The Immunohistochemistry Market is projected to reach US$ 3,585.31 million by 2028, up from US$ 2,171.61 million in 2021, expanding at a CAGR of 7.4% from 2021 to 2028. Market growth is being supported by the increasing prevalence of cancer, rising demand for accurate disease diagnosis, growing adoption of personalized medicine, and continued advancements in immunohistochemistry techniques, antibodies, reagents, and automated laboratory systems.
What is driving the market?
The increasing incidence of cancer and growing demand for accurate tissue-based diagnosis are major factors driving the global immunohistochemistry market. Immunohistochemistry enables laboratories and pathologists to identify specific proteins and biomarkers within tissue samples, supporting disease classification, diagnosis, prognosis, and treatment selection.
The rising global burden of cancer is increasing the need for reliable diagnostic and pathological testing. Immunohistochemistry plays an important role in identifying tumor characteristics and differentiating between cancer subtypes, making it an important tool in modern pathology and oncology.
Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00006184
Which region leads?
North America is expected to remain a leading region in the immunohistochemistry market, supported by advanced healthcare infrastructure, high adoption of diagnostic technologies, and significant investment in cancer research and pathology. The United States represents an important market due to its established clinical laboratory network and growing demand for advanced diagnostic and biomarker testing.
Europe also represents a significant market, supported by established pathology services, increasing cancer diagnostics, and continued adoption of automated laboratory technologies. The region’s focus on improving diagnostic accuracy and expanding personalized healthcare is supporting demand for immunohistochemistry products.
Asia Pacific is expected to provide significant growth opportunities as healthcare infrastructure expands and access to advanced diagnostic technologies improves. Rising cancer incidence, increasing healthcare expenditure, and growing awareness of early disease detection are contributing to the adoption of immunohistochemistry across emerging markets.
Which segment leads?
Antibodies represent a major product segment in the immunohistochemistry market, reflecting their central role in detecting specific proteins and biomarkers in tissue samples. Primary and secondary antibodies are widely used in immunohistochemical procedures and support diagnostic applications across oncology and other disease areas.
The market is also supported by reagents, kits, staining systems, and related instruments. Automated immunohistochemistry platforms are gaining importance as laboratories seek to improve workflow efficiency, standardization, reproducibility, and throughput.
Oncology represents a key application area because immunohistochemistry is extensively used to characterize tumors and identify biomarkers relevant to diagnosis and treatment selection. Applications in infectious diseases, autoimmune disorders, and other pathological conditions also contribute to overall market demand.
Which companies are prominent?
The global immunohistochemistry market includes major life-science, diagnostics, and biotechnology companies competing through antibody portfolios, reagent development, automated platforms, and laboratory technologies. Prominent participants include F. Hoffmann-La Roche AG, Merck KGaA, PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Abcam Plc, Agilent Technologies, Bio SB, Bio-Rad Laboratories, Cell Signaling Technology, Inc., and Danaher Corporation.
Competition is increasingly influenced by the breadth and quality of antibody portfolios, diagnostic performance, automation capabilities, and integration with digital pathology workflows. Companies are also investing in technologies that can improve testing accuracy, laboratory productivity, and biomarker detection.
The companies listed above represent prominent participants in the industry and are not presented as a revenue-ranked market-share table. Competitive positioning can vary across antibodies, reagents, instruments, applications, and geographic markets.
What is changing in 2026?
In 2026, the immunohistochemistry market is increasingly moving toward automation, digital pathology, and more precise biomarker-based diagnostic workflows. Laboratories are adopting automated staining platforms and standardized workflows to reduce manual processing, improve consistency, and increase testing capacity.
Digital pathology is also creating new opportunities for the integration of immunohistochemistry with image analysis. Advanced imaging and software-based analysis can support pathologists in evaluating tissue samples and identifying clinically relevant biomarkers more efficiently.
Another important trend is the increasing role of immunohistochemistry in personalized medicine. As targeted therapies and biomarker-driven treatment strategies expand, demand is growing for diagnostic methods capable of accurately identifying molecular and protein markers that can influence treatment decisions.
Purchase a Copy of this report: https://www.theinsightpartners.com/buy/TIPRE00006184
What are the major investment opportunities?
Investment opportunities in the immunohistochemistry market are emerging across advanced antibodies, automated staining systems, digital pathology, image analysis, and biomarker-focused diagnostic technologies. Companies developing highly specific antibodies and reliable reagents can benefit from increasing demand for accurate tissue-based testing.
Automation represents another important opportunity as clinical laboratories seek to improve efficiency and manage growing diagnostic workloads. Automated staining instruments, reagent systems, and integrated laboratory workflows can help reduce manual intervention while improving consistency.
Digital pathology and artificial intelligence-enabled image analysis also offer long-term growth potential. The integration of immunohistochemistry with digital imaging technologies can support more efficient interpretation of tissue samples and expand the role of pathology in precision medicine. Continued investment in oncology diagnostics and biomarker testing is expected to support market opportunities through 2028.
Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish
Related Reports:
CRISPR and Cas Gene Market Share & Growth 2031
Epigenetics Market Growth, Share & Forecast 2031
About Us
The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.
Contact US
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
E-mail : sales@theinsightpartners.com
